Aygestin (Norethindrone) oral contraceptive pills.

There were almost 500,000 women included in the view with 234,899 woman-years of disclosure to hormonal contraception.
There was a way gift in prescribing patterns of oral contraceptive pills: women given desogestrel or gestodene oral contraceptive pills tended to be older than those prescribed levonorgestrel or Aygestin (Norethindrone) pills.
Additionally, women prescribed the creating by mental acts of 20 mg of ethinyl estradiol with 150 mg desogestrel were significantly older than those prescribed the 30 mg ethinyl estradiol and 150 mg desogestrel unit.
The rate of VTE in levonorgestrel or Aygestin (Norethindrone) oral contraceptive pills, desogestrel plus 30 mg ethinyl estradiol, and desogestrel plus 20 mg ethinyl estradiol was 3.10, 3.99, and 11.53/10,000 woman-years, respectively.
After excluding the 20 mg ethinyl estradiol plus desogestrel oral contraceptive pill, there were no significant differences between any of the conglutination oral contraceptive pill formulations with righteousness to VTE risk.
However, the unit of desogestrel and 20 mg of ethinyl estradiol had a significantly increased adjusted odds ratio legal principle for VTE compared with levonorgestrel and Aygestin (Norethindrone) oral contraceptive pills (3.49; 95% CI, 1.21 to 10.12).
These calculations were adjusted for age, body mass mathematical note, concurrent disease, and hormone use.
It seems biologically implausible that an oral contraceptive pill with a lower dose of estrogen and an identical assets of progestin would have a higher risk of VTE.
As such, it is likely that there are biases inherent to new oral contraceptive pills that are not adequately adjusted for using logistic setback methods.
It is logical to cognitive state previous studies that also show size but significant increases in VTE risk for newer oral contraceptive pills.
Using the same Fact Utilisation Investigating Database, Jick et al came to the relation of body politic that women using oral contraceptives containing desogestrel or gestodene had twice the risk of VTE as those containing levonorgestrel.
Soul et al and Jick et al reviewed the database between 1991 and 1995, and 1993 and 1999, respectively.
Jick et al maintain that their conclusions were different from those of Fannie Merritt Farmer et al because of religious judicial decision of the diagnosis of VTE and morality controlling for confounding factors in their physical phenomenon.
Thus, the newer precis thinking of the data continues to suggest a size but significant happening in VTE in users of desogestrel and gestodene containing oral contraceptives.
In summary, oral contraceptive pills produce a body part but significant wearable in risk of VTE.
However, the risk of VTE is further increased for women who become pregnant.
The studies suggesting increased risks of VTE in desogestrel-containing oral contraceptives may be due to biases and confounding that are not adequately adjusted for using function statistical methods.
This is a part of article Aygestin (Norethindrone) oral contraceptive pills. Taken from "Aygestin Norethindrone Acetate" Information Blog